학술논문

Five-year outcome of children with idiopathic nephrotic syndrome: the NEPHROVIR population-based cohort study.
Document Type
Article
Source
Pediatric Nephrology. Apr2019, Vol. 34 Issue 4, p671-678. 8p. 1 Diagram, 2 Charts, 4 Graphs.
Subject
*IMMUNOSUPPRESSIVE agents
*AGE factors in disease
*ETHNIC groups
*INTRAVENOUS therapy
*LONGITUDINAL method
*MEDICAL cooperation
*MEDICAL protocols
*NEPHROTIC syndrome
*RESEARCH
*SEX distribution
*STEROIDS
*DISEASE remission
*DISEASE prevalence
*CHILDREN
DISEASE relapse prevention
Language
ISSN
0931-041X
Abstract
Background: The optimal therapeutic regimen for children at onset of idiopathic nephrotic syndrome (INS) is still under debate. A better knowledge of the disease's course is necessary to design more appropriate and/or personalized treatment protocols.Methods: We report the 5-year outcome of patients included from December 2007 to May 2010 in the prospective multicentric and multiethnic population-based NEPHROVIR study. Patients were treated at onset according to the French steroid protocol (3990 mg/m2, 18 weeks). Data were collected at 5 years or last follow-up.Results: Out of the 188 children with nephrotic syndrome (121 boys, 67 girls; median age 4.1 years), 174 (93%) were steroid-sensitive. Six percent of steroid-sensitive patients required intravenous steroid pulses to get into remission. Relapse-free rate for steroid-sensitive patients was 21% (36/174) at last follow-up (median 72 months). A first relapse occurred in138 steroid sensitive patients (79%) with a median time of 8.3 months (IQ 3.4-11.3). Out of the 138 relapsers, 43 were frequent relapsers. Age at onset below 4 years was the only predictive factor of relapse, while gender, ethnicity, and delay to first remission were not. At 96 months of follow-up, 83% of frequent relapsers were still under steroids and/or immunosuppressive drugs.Conclusions: The treatment of the first flare deserves major improvements in order to reduce the prevalence of relapsers and the subsequent long-lasting exposure to steroids and immunosuppression. [ABSTRACT FROM AUTHOR]